NRSN ▼ -6.2% - NeuroSense Therapeutics Ltd.
$NRSN NRSN - NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
29-OCT-2026 11:31 AM ET
Share this post
More filings for $NRSN
NRSN ▼ -2.4% - NeuroSense Therapeutics Ltd.Oct 26, 2026NRSN ▼ -8.1% - NeuroSense Therapeutics Ltd.Oct 19, 2026NRSN ▼ -19.0% - NeuroSense Therapeutics Ltd.Sep 28, 2026NRSN ▼ -2.3% - NeuroSense Therapeutics Ltd.Sep 25, 2026NRSN ▼ -7.5% - NeuroSense Therapeutics Ltd.Sep 10, 2026NRSN ▲ +9.5% - NeuroSense Therapeutics Ltd.Aug 31, 2026
View full $NRSN filing history →💬 Comments
Loading comments…
Leave a comment